Mesoblast Reports Increased Revenue and Improved Operating Spend
Key points
- 44% increase in Ryoncil® net revenue
- 85% improvement in net operating cash spend
- Strong cash position of $99 million at September 30, 2026
Full summary
Mesoblast Limited (ASX:MSB; Nasdaq:MESO) announced a 44% increase in net revenue from Ryoncil sales and an 85% improvement in net operating cash spend for the period ending September 30, 2026, compared to the same period last year. The company's strong cash position stood at $99 million as of September 30, 2026, driven by disciplined capital allocation and revenue growth. Mesoblast plans to continue expanding its market penetration and adoption across 54 onboarded sites while maintaining focus on commercial manufacturing and late-stage clinical programs.
Summary generated by a large language model. Please interpret with care.